Introduction
Quinupristin/dalfopristin is a water-soluble derivative of a natural product that contains ca. 30% quinupristin and ca. 70% dalfopristin. The product is intended for parenteral administration. Another streptogramin, RPR 106,972, is administered orally. The in-vitro activities of the two streptogramins are essentially identical. 1, 2 They are active against most Gram-positive cocci, including vancomycinresistant Enterococcus faecium, methicillin-resistant Staphylococcus spp. and erythromycin-resistant Streptococcus pneumoniae. 1, [3] [4] [5] [6] [7] The purpose of the current report is to document the prevalence of streptogramin resistance among 2481 recent clinical isolates of Gram-positive cocci collected from ten different medical centres. In addition, previously proposed 8 interpretative criteria for 15 g quinupristin/dalfopristin disc susceptibility tests were further evaluated.
Materials and methods
Broth microdilution and disc diffusion susceptibility tests were performed according to the methods outlined by the National Committee for Clinical Laboratory Standards.
9,10
Erythromycin was the control antibiotic included in all tests. The two streptogramins were obtained from Rhône-Poulenc-Rorer Central Research, Collegeville, PA, USA. The 15 g quinupristin/dalfopristin discs were produced by Remel, Lenexa, KS, USA.
The clinical isolates were collected during the winter months of 1996-1997. The ten laboratories that contributed fresh isolates are listed in the Acknowledegments at the end of this report. The bacterial isolates represent consecutive collections, except that multiple isolates from the same patient episode were excluded. The species represented are identified in the Table. Appropriate biochemical tests were used to confirm the identity of each isolate when the original species identification was questioned because of unexpected colony morphology or antimicrobial resistance patterns.
Results and discussion
The Table displays the distribution of MICs for each species or subgroup. Erythromycin had little useful activity against the enterococci. Isolates of Enterococcus faecalis were relatively resistant to both streptogramins, but isolates of Enterococcus faecium were much more susceptible.
Unlike the enterococci, staphylococci were less susceptible to RPR 106,972 than to quinupristin/dalfopristin, but the potencies differed by only one or two doubling concentrations. Most (75-95%) oxacillin-resistant staphylococci were also resistant to erythromycin, but they were susceptible to both streptogramins. Only 21-38% of oxacillin-susceptible staphylococci were erythromycinresistant. Both streptogramins were active against all staphylococci included in this series. Against macrolide-susceptible pneumococci, erythromycin was eight times more potent than quinupristindalfopristin and four times more potent than RPR 106,972. The macrolide-resistant pneumococci are especially problematic because they tend to be resistant to penicillin and to many other antimicrobial agents. Both streptogramins were active against erythromycin-resistant pneumococci, although RPR 106,972 was twice as active as quinupristin/dalfopristin.
Interpretative criteria that were previously proposed for disc diffusion susceptibility tests of quinupristin/ dalfopristin were evaluated against this large series of contemporary bacterial isolates. The agreement between interpretative categories (MIC 1.0 mg/L for susceptible and MIC 4.0 mg/L for resistant) was compared with those for disc tests ( 19 mm for susceptible and 15 mm for resistant). The staphylococci and enterococci were tested without added blood and without incubating in increased CO 2 concentrations. Tests with 1484 such isolates displayed 91% total interpretative agreement and 7% had discrepancies involving an intermediate category for one test, but not the other (minor errors). Most of the 1.9% major or very major discrepancies involved tests of enterococci.
Susceptibility tests of the Streptococcus spp. were evaluated separately because they required the addition of 3% lysed horse blood to the broth media or 5% sheep blood to the agar media and because tests on agar media were also incubated in 5-7% CO 2 . Since the vast majority of isolates were very susceptible to quinupristin/ dalfopristin, discrepant disc tests were uncommon (with error rates of 0.3% very major, 0.2% major and 5.4% minor). None of the 545 pneumococci were resistant to quinupristin/dalfopristin and only seven of 452 nonpneumococcal streptococci were resistant as judged by microdilution tests: three of those seven resistant isolates were susceptible as judged by the disc test.
The provisional zone-size interpretative criteria that have been proposed for tests of quinupristin/dalfopristin 8 were substantiated by the data noted above. However, there is need for a correlation with clinical and bacteriological responses of infected patients before any interpretative criteria can be finalized. RPR 106,972 discs have yet to be studied.
A major advantage of the streptogramins is their ability to inhibit macrolide-resistant strains. As demonstrated by this survey of pathogens currently being encountered in North America, macrolide-resistance occurs most frequently among oxacillin-resistant staphylococci, penicillinresistant or penicillin-intermediate pneumococci and the enterococci. Both streptogramins display in-vitro activity against E. faecium isolates, including vancomycin-resistant strains. 1, 3 However, E. faecalis isolates tend to be resistant to both streptogramins. RPR 106,972 and quinupristin/ dalfopristin have nearly identical spectra of in-vitro activity, but the clinical effectiveness of the oral drug is yet to be documented.
